» Articles » PMID: 11312327

Equine Infectious Anemia Virus Genomic Evolution in Progressor and Nonprogressor Ponies

Overview
Journal J Virol
Date 2001 Apr 20
PMID 11312327
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

A primary mechanism of lentivirus persistence is the ability of these viruses to evolve in response to biological and immunological selective pressures with a remarkable array of genetic and antigenic variations that constitute a perpetual natural experiment in genetic engineering. A widely accepted paradigm of lentivirus evolution is that the rate of genetic variation is correlated directly with the levels of virus replication: the greater the viral replication, the more opportunities that exist for genetic modifications and selection of viral variants. To test this hypothesis directly, we examined the patterns of equine infectious anemia virus (EIAV) envelope variation during a 2.5-year period in experimentally infected ponies that differed markedly in clinical progression and in steady-state levels of viral replication as indicated by plasma virus genomic RNA assays. The results of these comprehensive studies revealed for the first time similar extents of envelope gp90 variation in persistently infected ponies regardless of the number of disease cycles (one to six) and viremia during chronic disease. The extent of envelope variation was also independent of the apparent steady-state levels of virus replication during long-term asymptomatic infection, varying from undetectable to 10(5) genomic RNA copies per ml of plasma. In addition, the data confirmed the evolution of distinct virus populations (genomic quasispecies) associated with sequential febrile episodes during acute and chronic EIA and demonstrated for the first time ongoing envelope variation during long-term asymptomatic infections. Finally, comparison of the rates of evolution of the previously defined EIAV gp90 variable domains demonstrated distinct differences in the rates of nucleotide and amino acid sequence variation, presumably reflecting differences in the ability of different envelope domains to respond to immune or other biological selection pressures. Thus, these data suggest that EIAV variation can be associated predominantly with ongoing low levels of virus replication and selection in target tissues, even in the absence of substantial levels of plasma viremia, and that envelope variation continues during all stages of persistent infection as the virus successfully avoids clearance by host defense mechanisms.

Citing Articles

High Genomic Variability in Equine Infectious Anemia Virus Obtained from Naturally Infected Horses in Pantanal, Brazil: An Endemic Region Case.

Malossi C, Fioratti E, Cardoso J, Magro A, Kroon E, Aguiar D Viruses. 2020; 12(2).

PMID: 32059508 PMC: 7077297. DOI: 10.3390/v12020207.


Equine infectious anemia virus in China.

Wang H, Rao D, Fu X, Hu M, Dong J Oncotarget. 2018; 9(1):1356-1364.

PMID: 29416700 PMC: 5787444. DOI: 10.18632/oncotarget.20381.


Amino acid mutations in the env gp90 protein that modify N-linked glycosylation of the Chinese EIAV vaccine strain enhance resistance to neutralizing antibodies.

Han X, Zhang P, Yu W, Xiang W, Li X Virus Genes. 2016; 52(6):814-822.

PMID: 27572122 DOI: 10.1007/s11262-016-1382-2.


Horses naturally infected with EIAV harbor 2 distinct SU populations but are monophyletic with respect to IN.

Cervantes D, Ball J, Edwards J, Payne S Virus Genes. 2016; 52(1):71-80.

PMID: 26739458 DOI: 10.1007/s11262-015-1280-z.


Antibody escape kinetics of equine infectious anemia virus infection of horses.

Schwartz E, Nanda S, Mealey R J Virol. 2015; 89(13):6945-51.

PMID: 25878104 PMC: 4468492. DOI: 10.1128/JVI.00137-15.


References
1.
Harrold S, Cook S, Cook R, Rushlow K, Issel C, Montelaro R . Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids. J Virol. 2000; 74(7):3112-21. PMC: 111810. DOI: 10.1128/jvi.74.7.3112-3121.2000. View

2.
Oaks J, Ulibarri C, Crawford T . Endothelial cell infection in vivo by equine infectious anaemia virus. J Gen Virol. 1999; 80 ( Pt 9):2393-2397. DOI: 10.1099/0022-1317-80-9-2393. View

3.
Hammond S, Li F, McKeon Sr B, Cook S, Issel C, Montelaro R . Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus. J Virol. 2000; 74(13):5968-81. PMC: 112093. DOI: 10.1128/jvi.74.13.5968-5981.2000. View

4.
Ly A, Stamatatos L . V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J Virol. 2000; 74(15):6769-76. PMC: 112193. DOI: 10.1128/jvi.74.15.6769-6776.2000. View

5.
Kliks S, Contag C, Corliss H, Learn G, Rodrigo A, Wara D . Genetic analysis of viral variants selected in transmission of human immunodeficiency viruses to newborns. AIDS Res Hum Retroviruses. 2000; 16(13):1223-33. DOI: 10.1089/08892220050116998. View